6,661 reports of this reaction
4.2% of all METOCLOPRAMIDE reports
#4 most reported adverse reaction
DYSTONIA is the #4 most commonly reported adverse reaction for METOCLOPRAMIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 6,661 FDA adverse event reports linking METOCLOPRAMIDE to DYSTONIA. This represents approximately 4.2% of all 156,854 adverse event reports for this drug.
Patients taking METOCLOPRAMIDE who experience dystonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSTONIA is moderately reported among METOCLOPRAMIDE users, representing a notable but not dominant share of adverse events.
In addition to dystonia, the following adverse reactions have been reported for METOCLOPRAMIDE:
The following drugs have also been linked to dystonia in FDA adverse event reports:
DYSTONIA has been reported as an adverse event in 6,661 FDA reports for METOCLOPRAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSTONIA accounts for approximately 4.2% of all adverse event reports for METOCLOPRAMIDE, making it a notable side effect.
If you experience dystonia while taking METOCLOPRAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.